Combination of Ifosfamide, Paclitaxel, and Cisplatin for the Treatment of Metastatic and Recurrent Carcinoma of the Uterine Cervix: A Phase II Study of the Hellenic Cooperative Oncology Group
- 1 June 2002
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 85 (3) , 476-482
- https://doi.org/10.1006/gyno.2002.6649
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine CervixJournal of Clinical Oncology, 1999
- Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design.Journal of Clinical Oncology, 1998
- Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1997
- Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.Journal of Clinical Oncology, 1996
- The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a reviewInternational Journal of Gynecologic Cancer, 1993
- The calculation of received dose intensity.Journal of Clinical Oncology, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimatorsComputer Methods and Programs in Biomedicine, 1988
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958